-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-382 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-382 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-382 in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lefitolimod in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lefitolimod in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lefitolimod in Solid Tumor Drug Details: MGN-1703 (lefitolimod) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Colorectal Cancer Drug Details: ORM-5029 is under development for...
-
Track & Monitor
Genomics in pharma: gene silencing
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s gene silencing segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. The Small-Cell Lung Cancer market research report provides comprehensive information on the therapeutics under development for SCLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Gene therapy for cancers
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Gene therapy for cancers segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – lefitolimod
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry lefitolimod Drug Details MGN-1703 (lefitolimod) is under development for the treatment of solid tumors,...
-
Product Insights
Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Human Immunodeficiency Virus Pipeline market research report provides a comprehensive overview on the therapeutics under development for Human Immunodeficiency Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency...
-
Sector Analysis
Competitor Landscape: HIV
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the HIV market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher